{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T08:04:29Z","timestamp":1744013069796,"version":"3.37.3"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T00:00:00Z","timestamp":1629590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T00:00:00Z","timestamp":1629590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00406-021-01322-3","type":"journal-article","created":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T14:02:32Z","timestamp":1629640952000},"page":"583-590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-7690","authenticated-orcid":false,"given":"L.","family":"Malandain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Leygues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Thibaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,22]]},"reference":[{"issue":"5","key":"1322_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF et al (2012) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatr Off J World Fed Soc Biol Psychiatr 13(5):318\u2013378","journal-title":"World J Biol Psychiatr Off J World Fed Soc Biol Psychiatr"},{"issue":"1","key":"1322_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/15622975.2012.739708","volume":"14","author":"A Hasan","year":"2013","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF et al (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatr Off J World Fed Soc Biol Psychiatr 14(1):2\u201344","journal-title":"World J Biol Psychiatr Off J World Fed Soc Biol Psychiatr"},{"issue":"1","key":"1322_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5414\/CP202413","volume":"54","author":"C-L Hou","year":"2016","unstructured":"Hou C-L, Ma X-R, Zang Y, Jia F-J, Lin Y-Q, Chiu HFK et al (2016) Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China. Int J Clin Pharmacol Ther 54(1):36\u201342","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"14","key":"1322_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1001\/jama.2014.10109","volume":"312","author":"WW Fleischhacker","year":"2014","unstructured":"Fleischhacker WW (2014) Antipsychotic medications for schizophrenia. JAMA 312(14):1467\u20131468","journal-title":"JAMA"},{"issue":"2\u20133","key":"1322_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.schres.2011.11.021","volume":"134","author":"H Takeuchi","year":"2012","unstructured":"Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M (2012) Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms. Schizophr Res 134(2\u20133):219\u2013225","journal-title":"Schizophr Res"},{"issue":"3","key":"1322_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1192\/bjp.187.3.248","volume":"187","author":"W Gaebel","year":"2005","unstructured":"Gaebel W (2005) Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 187(3):248\u2013255","journal-title":"Br J Psychiatry"},{"issue":"1","key":"1322_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/schbul\/sbp130","volume":"36","author":"J Kreyenbuhl","year":"2010","unstructured":"Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB (2010) The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 36(1):94\u2013103","journal-title":"Schizophr Bull"},{"key":"1322_CR8","unstructured":"HAS Guide ALD 23 Schizophr\u00e9nies. June 2007. Available at: https:\/\/www.hassante.fr\/upload\/docs\/application\/pdf\/guide_ald23_schizophr_juin_07.pdf"},{"key":"1322_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/appi.ajp.161.1.1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO (2004) Practice guideline for the treatment of partients with schizophrenia second edition. Am J Psychiatr 161:1\u201356","journal-title":"Am J Psychiatr"},{"issue":"3","key":"1322_CR10","first-page":"87","volume":"17","author":"G Hung","year":"2007","unstructured":"Hung G (2007) A Comparison of Two Methods for Calculating Total Antipsychotic Dose. Hong Kong J Psychiatr 17(3):87\u201390","journal-title":"Hong Kong J Psychiatr"},{"issue":"2","key":"1322_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/0019-5545.111475","volume":"55","author":"G Venkatasubramanian","year":"2013","unstructured":"Venkatasubramanian G, Danivas V (2013) Current perspectives on chlorpromazine equivalents: comparing apples and oranges! Indian J Psychiatr 55(2):207","journal-title":"Indian J Psychiatr"},{"issue":"5","key":"1322_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0004867416641195","volume":"50","author":"C Galletly","year":"2016","unstructured":"Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E et al (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatr 50(5):410\u2013472","journal-title":"Aust N Z J Psychiatr"},{"key":"1322_CR13","doi-asserted-by":"publisher","unstructured":"Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, M\u00f6ller H-J; WFSBP Task Force on Treatment Guidelines for Schizophrenia, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthoj, Wagner F. Gattaz, Hans-J\u00fcrgen M\u00f6ller & WFSBP Task Force on Treatment Guidelines for Schizophrenia (2006) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 7(1):5\u201340. https:\/\/doi.org\/10.1080\/15622970500483177","DOI":"10.1080\/15622970500483177"},{"issue":"1","key":"1322_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA et al (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71\u201393","journal-title":"Schizophr Bull"},{"key":"1322_CR15","unstructured":"Browning B. Medicines Guideline: High-dose antipsychotic prescribing (MG01) [Internet]. 2018. Available from: http:\/\/www.awp.nhs.uk\/handlers\/downloads.ashx?id=16277. Accessed 20 Aug 2021"},{"key":"1322_CR16","unstructured":"Royal College of Psychiatrists. Consensus statement on high-dose antipsychotic medication [Internet]. November 2014. Available from: https:\/\/www.rcpsych.ac.uk\/docs\/default-source\/members\/facultiesrehabilitation-and-social-psychiatry\/rehabcr190.pdf?sfvrsn=d8397218_4. Accessed 20 Aug 2021"},{"key":"1322_CR17","unstructured":"A Systematic Review of Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2011 Dec. (CADTH Optimal Use Report, No. 1.1B.) 2, ISSUE. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK169721\/. Accessed 20 Aug 2021"},{"issue":"04","key":"1322_CR18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1192\/bjp.164.4.448","volume":"164","author":"C Thompson","year":"1994","unstructured":"Thompson C (1994) The use of high-dose antipsychotic medication. Br J Psychiatry 164(04):448\u2013458","journal-title":"Br J Psychiatry"},{"issue":"2","key":"1322_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","volume":"24","author":"JM Davis","year":"2004","unstructured":"Davis JM, Chen N (2004) Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24(2):192\u2013208","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1322_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/oxfordjournals.schbul.a007112","volume":"30","author":"DL Leslie","year":"2004","unstructured":"Leslie DL, Rosenheck RA (2004) Adherence of schizophrenia pharmacotherapy to published treatment recommendations: patient, facility, and provider predictors. Schizophr Bull 30(3):649\u2013658","journal-title":"Schizophr Bull"},{"issue":"4","key":"1322_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.euroneuro.2014.01.014","volume":"24","author":"MX Patel","year":"2014","unstructured":"Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ et al (2014) Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 24(4):499\u2013509","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"issue":"2","key":"1322_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1365-2125.2004.02102.x","volume":"58","author":"K Sim","year":"2004","unstructured":"Sim K, Su A, Fujii S, Yang S, Chong M-Y, Ungvari GS et al (2004) Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58(2):178\u2013183","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1322_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1192\/bjp.bp.107.042895","volume":"192","author":"C Paton","year":"2008","unstructured":"Paton C, Barnes TRE, Cavanagh M-R, Taylor D, Lelliott P, The POMH-UK project team (2008) High dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 192(6):435\u2013439","journal-title":"Br J Psychiatry"},{"issue":"6","key":"1322_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/01.yic.0000224785.68040.43","volume":"21","author":"C Barbui","year":"2006","unstructured":"Barbui C, Nos M, Mazzi MA, Thornicroft G, Schene A, Becker T et al (2006) Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 21(6):355\u2013362","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"1322_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/13651500600811206","volume":"10","author":"M De Hert","year":"2006","unstructured":"De Hert M, Wampers M, Peuskens J (2006) Pharmacological treatment of hospitalised schizophrenic patients in Belgium. Int J Psychiatry Clin Pract 10(4):285\u2013290","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"8","key":"1322_CR26","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1176\/appi.ajp.161.8.1324","volume":"161","author":"MV Seeman","year":"2004","unstructured":"Seeman MV (2004) Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 161(8):1324\u20131333","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1322_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0013-7006(06)76165-6","volume":"32","author":"I Lamarque","year":"2006","unstructured":"Lamarque I, Auffray L, Villamaux M, Demant J-C, Launay C, Petitjean F et al (2006) Analyse du profil socio-d\u00e9mographique et clinique de patients schizophr\u00e8nes en fonction du traitement neuroleptique re\u00e7u. L\u2019Enc\u00e9phale 32(3):369\u2013376","journal-title":"L\u2019Enc\u00e9phale"},{"issue":"5","key":"1322_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/pcn.12056","volume":"67","author":"J Fujita","year":"2013","unstructured":"Fujita J, Nishida A, Sakata M, Noda T, Ito H (2013) Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia: polypharmacy caused by p.r.n. medication. Psychiatry Clin Neurosci 67(5):345\u2013351","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"1322_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/070674379704200108","volume":"42","author":"GJ Remington","year":"1997","unstructured":"Remington GJ, Prendergast P, Bezchlibnyk-Butler KZ (1997) Neuroleptic dosing in chronic schizophrenia: a 10\u00a0year follow-up. Can J Psychiatry 42(1):53\u201357","journal-title":"Can J Psychiatry"},{"key":"1322_CR30","doi-asserted-by":"publisher","unstructured":"Thomas P, Gossell-Williams M, Sewell C, Abel W, McGrowder D, Martin J (2015) The impact of cannabis use on the dosage of antipsychotic drugs for patients admitted on the psychiatric ward at the University Hospital of the West Indies. WIMJ Open 2(1):  23\u201327. https:\/\/doi.org\/10.7727\/wijmopen.2014.259. Available from: http:\/\/www.mona.uwi.edu\/wimjopen\/article\/1618. Accessed 20 Aug  2021","DOI":"10.7727\/wijmopen.2014.259"},{"issue":"05","key":"1322_CR31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1192\/apt.6.5.327","volume":"6","author":"C Kelly","year":"2000","unstructured":"Kelly C, McCreadie R (2000) Cigarette smoking and schizophrenia. Adv Psychiatr Treat 6(05):327\u2013331","journal-title":"Adv Psychiatr Treat"},{"key":"1322_CR32","unstructured":"Lecrubier Y, Weiller E, Hergueta T, Amorim P, Bonora LI, Lepine JP (2006) Mini International Neuropsychiatric Interview English Version 5.0.0. Available at: https:\/\/huibee.com\/wordpress\/wp-content\/uploads\/2013\/11\/Mini-International-Neuropsychiatric-Interview-MINI.pdf"},{"key":"1322_CR33","doi-asserted-by":"crossref","unstructured":"Guy W (1976) Clinical Global Impressions, ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ. No. ADM 76-338). National Institute of Mental Health, Rockville, pp 218\u2013222","DOI":"10.1037\/e591322011-001"},{"key":"1322_CR34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799\u2013812","journal-title":"Psychol Rep"},{"key":"1322_CR35","unstructured":"American Psychiatric Association (APA) (2000) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) Washington, DC, USA"},{"key":"1322_CR36","unstructured":"WHO (2013) Guidelines for ATC classification and DDD assignment 2013 [Internet]. Available from: https:\/\/www.whocc.no\/filearchive\/publications\/1_2013guidelines.pdf. Accessed 20 Aug 2021"},{"issue":"2","key":"1322_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jsps.2013.03.003","volume":"22","author":"WM Sweileh","year":"2014","unstructured":"Sweileh WM, Odeh JB, Shraim NY, Zyoud SH, Sawalha AF, Al-Jabi SW (2014) Evaluation of defined daily dose, percentage of british national formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization. Saudi Pharm J 22(2):127\u2013132","journal-title":"Saudi Pharm J"},{"issue":"5","key":"1322_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/YIC.0b013e328303ac75","volume":"23","author":"M Nos\u00e8","year":"2008","unstructured":"Nos\u00e8 M, Tansella M, Thornicroft G, Schene A, Becker T, Veronese A et al (2008) Is the defined daily dose system a reliable tool for standardizing antipsychotic dosages? Int Clin Psychopharmacol 23(5):287\u2013290","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"1322_CR39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/01.jcp.0000096247.29231.3a","volume":"23","author":"CAW Rijcken","year":"2003","unstructured":"Rijcken CAW, Monster TBM, Brouwers JRBJ, de JongvandenBerg LTW (2003) Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacol 23(6):657\u2013659","journal-title":"J Clin Psychopharmacol"},{"issue":"1\u20133","key":"1322_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.schres.2013.06.030","volume":"149","author":"MX Patel","year":"2013","unstructured":"Patel MX, Arista IA, Taylor M, Barnes TRE (2013) How to compare doses of different antipsychotics: a systematic review of methods. Schizophr Res 149(1\u20133):141\u2013148","journal-title":"Schizophr Res"},{"issue":"suppl 1","key":"1322_CR41","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S, Samara M, Heres S, Davis JM (2016) Dose Equivalents for Antipsychotic drugs: the DDD Method: table 1. Schizophr Bull 42(suppl 1):S90\u2013S94","journal-title":"Schizophr Bull"},{"issue":"3 Pt 1","key":"1322_CR42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0013-7006(07)92046-1","volume":"33","author":"A Grolleau","year":"2007","unstructured":"Grolleau A, Cougnard A, Parrot M, Kalmi E, Desage A, Misdrahi D et al (2007) Prescription practices of antipsychotic medication in early psychosis: a two-year follow-up survey of subjects admitted in two psychiatric hospitals of South-Western France. L\u2019Encephale 33(3 Pt 1):326\u2013331","journal-title":"L\u2019Encephale"},{"issue":"4","key":"1322_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/YIC.0b013e3281084ea8","volume":"22","author":"C Barbui","year":"2007","unstructured":"Barbui C, Biancosino B, Esposito E, Marmai L, Don\u00e0 S, Grassi L (2007) Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 22(4):221\u2013225","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"1322_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/2141-9248.109499","volume":"3","author":"B James","year":"2013","unstructured":"James B, Adesola A, Anozie I, Erohubie P (2013) Prevalence and correlates of \u201chigh dose\u201d antipsychotic prescribing: findings from a hospital audit. Ann Med Health Sci Res 3(1):62","journal-title":"Ann Med Health Sci Res"},{"issue":"4","key":"1322_CR45","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/j.1440-1614.2004.01340.x","volume":"38","author":"V Humberstone","year":"2004","unstructured":"Humberstone V, Wheeler A, Lambert T (2004) An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust N Z J Psychiatry 38(4):240\u2013245","journal-title":"Aust N Z J Psychiatry"},{"key":"1322_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.05.015","author":"L Malandain","year":"2017","unstructured":"Malandain L, Thibaut F, Grimaldi-Bensouda L, Falissard B, Abenhaim L, Nordon C et al (2017) Correlates and predictors of antipsychotic drug polypharmacy in real-life settings: results from a nationwide cohort study. Schizophr Res. https:\/\/doi.org\/10.1016\/j.schres.2017.05.015","journal-title":"Schizophr Res"},{"key":"1322_CR47","volume-title":"Prescrire les antipsychotiques","author":"N Franck","year":"2015","unstructured":"Franck N, Thibaut F (2015) Prescrire les antipsychotiques. Elsevier, Masson"},{"issue":"1\u20133","key":"1322_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.schres.2006.08.017","volume":"89","author":"CU Correll","year":"2007","unstructured":"Correll CU, Frederickson AM, Kane JM, Manu P (2007) Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 89(1\u20133):91\u2013100","journal-title":"Schizophr Res"},{"issue":"1","key":"1322_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","volume":"138","author":"JA Gallego","year":"2012","unstructured":"Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138(1):18\u201328","journal-title":"Schizophr Res"},{"issue":"12","key":"1322_CR50","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209\u20131223","journal-title":"N Engl J Med"},{"issue":"1","key":"1322_CR51","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S0014-3855(02)00110-X","volume":"67","author":"D Gourion","year":"2002","unstructured":"Gourion D, Spadone C (2002) Utilisation des antipsychotiques \u00e0 doses \u00e9lev\u00e9es. Evol Psychiatr 67(1):184\u2013198","journal-title":"Evol Psychiatr"},{"issue":"1\u20133","key":"1322_CR52","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.schres.2015.04.024","volume":"166","author":"M Dold","year":"2015","unstructured":"Dold M, Fugger G, Aigner M, Lanzenberger R, Kasper S (2015) Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Res 166(1\u20133):187\u2013193","journal-title":"Schizophr Res"},{"issue":"1","key":"1322_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0246-1072(05)32572-7","volume":"3","author":"N Franck","year":"2006","unstructured":"Franck N, Thibaut F (2006) Pharmacologie et mode d\u2019action des neuroleptiques. EMC Psychiatr 3(1):1\u201312","journal-title":"EMC Psychiatr"},{"issue":"6","key":"1322_CR54","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.neubiorev.2005.02.006","volume":"29","author":"V Kumari","year":"2005","unstructured":"Kumari V, Postma P (2005) Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 29(6):1021\u20131034","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"1322_CR55","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/BF02246063","volume":"119","author":"JP McEvoy","year":"1995","unstructured":"McEvoy JP, Freudenreich O, Levin ED, Rose JE (1995) Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 119(1):124\u2013126","journal-title":"Psychopharmacology"},{"issue":"6","key":"1322_CR56","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2165\/00003088-199936060-00004","volume":"36","author":"S Zevin","year":"1999","unstructured":"Zevin S, Benowitz NL (1999) Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 36(6):425\u2013438","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1322_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1017\/S003329170002729X","volume":"24","author":"P Bollini","year":"1994","unstructured":"Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC (1994) Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials. Psychol Med 24(2):307\u2013316","journal-title":"Psychol Med"},{"issue":"3","key":"1322_CR58","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/schbul\/sbu164","volume":"41","author":"M Torniainen","year":"2015","unstructured":"Torniainen M, Mittendorfer-Rutz E, Tanskanen A, Bj\u00f6rkenstam C, Suvisaari J, Alexanderson K et al (2015) Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 41(3):656\u2013663","journal-title":"Schizophr Bull"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-021-01322-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-021-01322-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-021-01322-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T21:06:11Z","timestamp":1675631171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-021-01322-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,22]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1007\/s00406-021-01322-3","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"type":"print","value":"0940-1334"},{"type":"electronic","value":"1433-8491"}],"subject":[],"published":{"date-parts":[[2021,8,22]]},"assertion":[{"value":"10 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LM and ML have no conflict of interest to declare. Florence Thibaut is Editor-in-Chief of Dialogues in Clinical Neurosciences, the journal received a grant from Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}